TWI845257B - Method for manufacturing water solubility oxide wound dressing - Google Patents

Abstract

The invention provides a method for manufacturing a water solubility oxide wound dressing, comprising: providing distilled water; adding an aqueous solution of oxide salts to the water to form a diluted aqueous solution of oxide salts; passing the diluted aqueous oxide salt solution through an activated carbon adsorption filter to remove trace hydrophobic harmful substances; introducing the diluted oxide salt solution into the magnetization reactor through a flow control valve for a synthesis reaction to form concentrated active oxide water; and adding concentrated active oxide water to water solubility polymers and distilled water to form water solubility oxide wound dressings. Therefore, the dressing obtained by the manufacturing method of the present invention has a function of supplying oxygen, and the dressing can accelerate the healing of various types of wounds and can more effectively protect the active ingredient and achieve the effect of sustained release, thereby increasing the therapeutic activity and reducing epidermal irritation and side effects.

Description

Manufacturing method of water-soluble oxide wound dressing

The present invention relates to a method for manufacturing a water-soluble oxide wound dressing, and in particular to a method for manufacturing a water-soluble oxide wound dressing that can protect active ingredients and achieve a sustained release effect.

The skin is the largest organ in the human body. It is used to cover the soft layer of vertebrates. The skin blocks foreign invasion and retains moisture. It has the functions of warmth, insulation, and sensation. Therefore, when there are wounds on the skin, such as those caused by general trauma or bedsores, the skin will be adversely affected and unable to perform its normal functions.

There are many types of wound dressings on the market. Usually, appropriate wound dressings are selected according to the different properties of the wound, and provide a good healing environment for the wound, block foreign matter and prevent various bacteria and viruses in the environment from invading the wound and causing infection. Secondly, the known way to treat the wound is to disinfect the wound first, then apply ointment and cover it with gauze, wait for the wound to heal by itself, and then remove the gauze and other external covering and fixing materials. However, for patients with large wounds or those with physical problems that are difficult to heal (such as diabetics), this method takes a long time to heal and requires multiple dressing changes. When the gauze is removed during the dressing change, the gauze and other covering materials often adhere to the tissue fluid of the wound, causing the wound to be torn again due to external force, resulting in further damage to the wound, requiring a longer healing time.

In view of this, the inventor is committed to combining moisture-retaining dressings with negative oxygen ions to form ionic gels, which is conducive to the rapid healing of wounds. The inventor has invested a lot of energy and spirit in research and development, and has continuously made breakthroughs and innovations in this field, hoping to solve the shortcomings of usage with novel technical means, not only to bring better products to the society, but also to promote industrial development.

The main purpose of the present invention is to provide a method for manufacturing a water-soluble oxide wound dressing. The water-soluble oxide wound dressing prepared by the manufacturing method is conducive to the dissolution of necrotic tissue and fibroprotein, and can promote the release of various growth factors in the exudate, thereby achieving the purpose of local moisturizing, reducing scab formation, avoiding mechanical damage to new granulation tissue, and reducing damage and pain when changing dressings. Secondly, the water-soluble oxide wound dressing of the present invention can form a closed moisturizing environment. The dressing forms a barrier to reduce the chance of wound infection, protect the nerve endings on the wound surface and reduce pain. At the same time, it can maintain a constant temperature on the wound surface, accelerate cell division to promote wound healing. The water-soluble oxide wound dressing can protect the active ingredients and achieve a sustained release effect.

To achieve the above-mentioned purpose of the present invention, the present invention provides a method for manufacturing a water-soluble oxide wound dressing, the method comprising the following steps: first, providing a distilled water or a mineral water, and adding an oxide salt aqueous solution into the distilled water or the mineral water to form a dilute oxide salt aqueous solution, wherein the oxide salt aqueous solution is formed by passing a high-pressure oxygen into a crystalline salt aqueous solution through a heating electrolysis method, the oxide salt aqueous solution has a pH value of about 5.5 to 8 and a volume molar concentration of 5 to 50 mol/L, and the heating temperature of the heating electrolysis method is controlled between 40 and 80° C. Secondly, the dilute oxide salt aqueous solution is passed through an activated carbon adsorption filter to remove trace hydrophobic harmful substances. Furthermore, the diluted oxide salt aqueous solution is introduced into a magnetizing reactor through a flow control valve to perform a synthesis reaction. The magnetizing reactor has a magnetic field of 0.1 to 1 Tesla and an electric field of 10 to 100 volts/cm. The synthesis temperature of the magnetizing reactor is controlled between 10°C and 55°C, the synthesis pressure is controlled at a high pressure of 6kg/ ^cm2 to 9kg/ ^cm2 , and the synthesis time is 30 to 90 minutes to form a concentrated active oxide water. In addition, the concentrated active oxide water is heated to 65-70° C., a water-soluble polymer and the distilled water or the mineral water are added and stirred for 3.5-4.5 hours, the stirring speed is controlled at 600-650 rpm, and then stirred for 5-6 hours under a vacuum state to form a water-soluble oxide wound dressing; wherein the water-soluble oxide wound dressing comprises: 45.0-55.0% of the distilled water or the mineral water, 15.0-25.0% of an aqueous solution of oxide salts and 30.0-35.0% of the water-soluble polymer, based on the total weight percentage of the water-soluble oxide wound dressing.

In the method for manufacturing the water-soluble oxide wound dressing of the present invention, the aqueous solution of the oxide salt has a volumetric molar concentration of 10-40 mol/L.

In the method for manufacturing the water-soluble oxide wound dressing of the present invention, the water-soluble polymer is sodium alginate, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, hyaluronic acid or any combination thereof.

In the manufacturing method of the water-soluble oxide wound dressing of the present invention, the water-soluble polymer includes: 1.0-30.0% sodium alginate, 1.0-25.0% polyvinyl pyrrolidone and 1.0-25.0% sodium carboxymethyl cellulose, based on the total weight percentage of the water-soluble oxide wound dressing.

The manufacturing method of the water-soluble oxide wound dressing of the present invention further includes an additive adding step, wherein the diluted oxide salt aqueous solution is introduced into an additive tank, and ozone is added into the additive tank for sterilization.

In the method for manufacturing the water-soluble oxide wound dressing of the present invention, the oxide salt aqueous solution is an aqueous solution composed of a metal element cation and a carbonate, sulfate, chromate, tungstate, molybdate, phosphate, arsenate or vanadate.

In the manufacturing method of the water-soluble oxide wound dressing of the present invention, the metal element cation includes at least one divalent or trivalent metal cation, which is Fe ²⁺ , Cu ²⁺ , Zn ²⁺ , Pb ²⁺ , Mn ²⁺ , Bi ³⁺ or any combination thereof.

In the manufacturing method of the water-soluble oxide wound dressing of the present invention, the thickness of the water-soluble oxide wound dressing is greater than 0.1 mm and less than 4 mm.

In the manufacturing method of the water-soluble oxide wound dressing of the present invention, the flow control valve controls the flow rate of the diluted oxide salt aqueous solution to 500~8000L/min.

In order to achieve the above-mentioned other purpose of the present invention, the present invention provides a water-soluble oxide wound dressing produced by the above-mentioned method for producing a water-soluble oxide wound dressing.

11: Storage tank

12: Activated carbon adsorption filter

13: Electrolytic magnetization device

14: Flow control valve

15:Magnetic Reactor

151: Water-soluble polymer

16: Add tank

FIG1 is a flow chart of the manufacturing method of the water-soluble oxide wound dressing of the present invention; FIG2 is a preparation system of the water-soluble oxide wound dressing of Example 1 of the present invention; FIG3 is a preparation system of the water-soluble oxide wound dressing of Example 2 of the present invention; FIG4A is a photograph of the affected part of the diabetic foot taken before the water-soluble oxide wound dressing of the present invention is applied; FIG4B is a photograph of the affected part of the diabetic foot taken 2 days after the water-soluble oxide wound dressing of the present invention is applied; and FIG4C is a photograph of the affected part of the diabetic foot taken 7 days after the water-soluble oxide wound dressing of the present invention is applied.

The following is a specific embodiment to illustrate the implementation of the present invention. People familiar with this art can easily understand the other advantages and effects of the present invention from the content disclosed in this manual. In addition, the present invention can also be implemented or applied through other different specific embodiments, and various modifications and changes can be made without deviating from the spirit of the present invention.

Implementation Example 1

Please refer to Figures 1 and 2. Figure 1 is a flow chart of the manufacturing method of the water-soluble oxide wound dressing of the present invention; and Figure 2 is a preparation system of the water-soluble oxide wound dressing of Example 1 of the present invention.

As shown in FIG. 1 and FIG. 2 , the present invention provides a method for manufacturing a water-soluble oxide wound dressing, the method comprising: step S101: providing a distilled water or a mineral water in a containing tank 11; step S102: adding an oxide salt aqueous solution into the distilled water or the mineral water to form a dilute oxide salt aqueous solution; wherein the oxide salt aqueous solution is formed by passing a high-pressure oxygen into a crystalline salt aqueous solution by a heated electrolysis method, and the oxide salt aqueous solution has a pH value of about 5.5 to 8 and a volume molar concentration of 5 to 50 mol/L; the oxide The salt aqueous solution preferably has a volume molar concentration of 10-40 mol/L, and the oxide salt aqueous solution more preferably has a volume molar concentration of 15-35 mol/L. The heating temperature of the heating electrolysis method is controlled between 40-80°C; wherein the oxide salt aqueous solution is an aqueous solution composed of a metal element cation and carbonate, sulfate, chromate, tungstate, molybdate, phosphate, arsenate or vanadate, the metal element cation includes at least one divalent or trivalent metal cation or any combination thereof, and the metal element cation is preferably Fe2 ⁺ , Cu2 ⁺ , Zn2 ⁺ , ^Pb2+ , Mn2 ⁺ or Bi3 ⁺ . Step S103: The aqueous solution mixed with the diluted oxide salts is passed through an activated carbon adsorption filter 12 to remove trace hydrophobic harmful substances. Step S104: The diluted oxide salts aqueous solution is introduced into a magnetizing reactor 15 through a flow control valve 14 to perform a synthesis reaction. The magnetizing reactor has a magnetic field between 0.1 and 1 Tesla and an electric field between 10 and 100 volts/cm. Therefore, when the diluted oxide salts aqueous solution passes through the magnetizing reactor 15, the charged particles in the water molecules are affected by the magnetic field and the electric field and move, thereby breaking the hydrogen bonds in the water molecules, so that the hydrogen bonds cover the oxide salts. In addition, the synthesis temperature of the magnetizing reactor 15 is controlled between 10°C and 55°C, the synthesis pressure is controlled between 6kg/ ^cm2 and 9kg/ ^cm2 , and the synthesis time is 30-90 minutes to form a diluted active oxide water. Step S105: Heat the diluted active oxide water to 65-70°C, add a water-soluble polymer 151 and the distilled water or the mineral water and stir for 3.5-4.5 hours, control the stirring speed at 600-650 rpm, and stir for 5-6 hours under vacuum to form a water-soluble oxide wound dressing; wherein, the water-soluble oxide wound dressing comprises: 45.0-55.0% of the total weight percentage of the active oxide wound dressing; Distilled water or mineral water, 15.0-25.0% aqueous solution of oxide salts and 30.0-35.0% water-soluble polymer 151, wherein the water-soluble polymer 151 is sodium alginate, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, hyaluronic acid or any combination thereof; the water-soluble polymer 151 comprises: 1.0-30.0% sodium alginate, 1.0-25.0% polyvinyl pyrrolidone and 1.0-25.0% sodium carboxymethyl cellulose, and the thickness of the water-soluble oxide wound dressing is greater than 0.1 mm and less than 4 mm, based on the total weight percentage of the water-soluble oxide wound dressing.

The water-soluble oxide wound dressing of the present invention adopts three-dimensional mesh water-based gel molecule technology, which is characterized by the fact that the hydrogel polymers are interconnected to form a spatial mesh structure, and the pores of the mesh structure are filled with liquid. The gel that undergoes cross-linking reaction has the characteristics of swelling but not dissolving due to the formation of a covalent cross-linking network. Due to the large number of hydrophilic groups in the hydrogel, it can absorb and retain a large amount of water. Therefore, the active oxide gel of the present invention has excellent biocompatibility, biodegradability, and is easy to synthesize, and has good permeability to low molecular weight solutes.

Wound healing test

Experimental animals 1

The animals used in the experiment were 8-week-old male New Zealand white rabbits weighing about 2000-2500g. All experimental animals1 were kept in an independent air-conditioned animal room with a room temperature maintained at 22°C and a relative humidity maintained at 45%, and water and feed were fully supplied. Before the experiment, the animals were given at least 4 weeks to adapt to the environment. The housing environment, handling and all experimental procedures of the experimental animals were in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.

Formation of skin wounds

The back of the New Zealand white rabbit was shaved, then disinfected with iodine and 70% alcohol, and a skin wound of approximately 2cm×2cm and 2~3mm deep was cut on the back of the New Zealand white rabbit using a scalpel.

Content of water-soluble oxide wound dressing ingredients

Experimental Group 1: The water-soluble oxide wound dressing comprises: 55% of the distilled water or the mineral water, 15.0% of an aqueous solution of oxide salts, 3.0% of sodium alginate, 2.0% of polyvinyl pyrrolidone and 25.0% of sodium carboxymethyl cellulose, based on the total weight percentage of the water-soluble oxide wound dressing.

Experimental Group 2: The water-soluble oxide wound dressing comprises: 55.0% of the distilled water or the mineral water, 20.0% of an aqueous solution of oxide salts, 3.0% of sodium alginate, 2% of polyvinyl pyrrolidone and 20.0% of sodium carboxymethyl cellulose, based on the total weight percentage of the water-soluble oxide wound dressing.

Control group 1: The water-soluble oxide wound dressing comprises: 55% of the distilled water or the mineral water, 15.0% of an aqueous solution of oxide salts, 3.0% of sodium alginate, 2.0% of polyvinyl pyrrolidone and 25.0% of sodium carboxymethyl cellulose, based on the total weight percentage of the water-soluble oxide wound dressing.

Control group 2: The water-soluble oxide wound dressing comprises: 55.0% of the mineral water or distilled water, 20.0% of an aqueous solution of oxide salts, 3.0% of sodium alginate, 2% of polyvinyl pyrrolidone and 20.0% of sodium carboxymethyl cellulose, based on the total weight percentage of the water-soluble oxide wound dressing.

Application of water-soluble oxide wound dressings

New Zealand white rabbits were randomly divided into 2 experimental groups and 2 control groups, wherein the New Zealand white rabbits in each group were formed with skin wounds according to the above method; then, the skin wounds of the New Zealand white rabbits in experimental groups 1 and 2 were respectively applied with the water-soluble oxide wound dressings according to the above experimental groups 1 and 2, and the wounds of the animals were covered with a polyurethane (PU) waterproof film to maintain moisture. The New Zealand white rabbits in control groups 1 and 2 were formed with skin wounds according to the above method; then, the skin wounds of the New Zealand white rabbits in control groups 1 and 2 were respectively applied with the water-soluble oxide wound dressings according to the above control groups 1 and 2. The experiment lasted a total of 14 days. The wound area of each group of New Zealand white rabbits was measured on the 2nd, 6th, 10th and 14th days after the application of the dressing. The results are shown in Table 1 below.

The difference between experimental group 1 and experimental group 2 lies in the oxygen content. The oxygen content of experimental group 2 is higher than that of experimental group 1. As can be seen from the table above, high oxygen content improves the wound closure rate. Secondly, experimental group 1 and experimental group 2 cover the wounds of animals with polyurethane waterproof film to keep the wounds moist, while control group 1 and control group 2 do not cover the wounds of animals with polyurethane waterproof film. As can be seen from the table above, the wounds heal faster in a humid environment. In summary, moist wound healing has the following advantages. First, it is conducive to the dissolution of necrotic tissue and fibroblasts. In a humid environment, the tissue protein dissolving enzymes in the wound exudate can promote the dissolution and absorption of necrotic tissue. Secondly, it regulates the oxygen tension of the wound surface and promotes the formation of capillaries. The hypoxic environment stimulates the proliferation of capillaries, which is beneficial to the formation of epithelial cells and collagen. Furthermore, it promotes the release of various growth factors in the exudate. The exudate retained in the wound surface releases and activates various enzymes and enzyme activation factors. The exudate can also effectively maintain the survival of cells, promote the release of various growth factors, and stimulate cell proliferation. In addition, it maintains a constant temperature on the wound surface, accelerates cell division, promotes wound healing, moisturizes the wound locally, reduces scab formation, avoids mechanical damage to new granulation tissue, reduces damage and pain when changing dressings, protects the nerve endings on the wound surface, and reduces pain. In addition, the closed moisturizing environment and the dressing form a barrier, which reduces the chance of infection. The slightly acidic environment in a closed state inhibits bacterial growth and is beneficial to the reproduction and function of white blood cells.

Experimental Animals 2

Experimental animals 2 were C57BL/6J Narl mice purchased from the National Laboratory Animal Center, weighing 40-45g and aged 8 weeks. All experimental animals 2 were kept in an independent air-conditioned animal room with a room temperature of 18-26℃ and a relative humidity of 30-70%, a light cycle of 12 hours of light and 12 hours of darkness, and sufficient water and feed. The breeding environment, handling and all experimental procedures of the experimental animals were in compliance with the National Institutes of Health's experimental animal breeding management and use regulations.

Non-infected wound care

Before the operation, the mice were given 0.6/kg of anesthetic by intraperitoneal injection. After the mice were anesthetized, the hair on their backs was shaved, and a skin wound of about 1.2cm×1.2cm was cut on the backs of the mice. Secondly, the mice were divided into a blank control group, a vaseline group, and an experimental group. The blank control group did not treat the wound; the vaseline group used a cotton swab to dip an appropriate amount of vaseline and evenly applied it to the wound; the experimental group used a cotton swab to dip an appropriate amount of water-soluble oxide wound dressing and evenly applied it to the wound.

Infected wound treatment

Before surgery, mice were given 0.6/kg of anesthetic by intraperitoneal injection. After the mice were anesthetized, their back hair was shaved and a skin wound of about 1.2cm×1.2cm was cut on the back of the mice. Staphylococcus aureus was diluted to 10 ⁵ CFU/150μl, and 150μl of bacterial solution was added to each mouse, allowing the bacterial solution to completely penetrate the skin for about 5 minutes. Secondly, the mice were divided into a blank control group, a vaseline group, and an experimental group. The blank control group did not treat the wound; the vaseline group used a cotton swab to dip an appropriate amount of vaseline and evenly applied it to the wound; the experimental group used a cotton swab to dip an appropriate amount of water-soluble oxide wound dressing and evenly applied it to the wound.

Wound tissue bacterial content test

On the seventh day of the mouse experiment, the purulent tissue of the back wound of the injured mouse was collected. The tissue was cut into pieces and crushed with an ultrasonic cell crusher. After centrifugation at 1,500rpm for 8 minutes at 4°C, the supernatant was collected. The supernatant was serially diluted, and the bacterial solution was evenly applied to the agar. After incubation in a 37°C incubator for about 16 hours, the number of colonies was calculated. The number of bacteria per gram of tissue (CFU/g) = (number of colonies * dilution multiple * 10/gram of tissue).

result

The changes in the appearance of wounds in non-infected mice were evaluated. After the wounds were made on the back skin of the mice, the wounds were cleaned and the medicines were changed every two days. Compared with other groups, the wounds of non-infected wounds treated with water-soluble oxide wound dressings had better healing efficiency. On the 8th to 10th day, the wounds of the blank control group and the vaseline group did not heal significantly. In contrast, the appearance of the wounds of the water-soluble oxide wound dressings had obviously begun to heal. The results in Table 2 show that after treatment with water-soluble oxide wound dressings, non-infected wounds can heal in about 8 to 10 days.

The changes in the appearance of the wounds of infected mice were evaluated. The wounds were infected with Staphylococcus aureus. After the seventh day of infection, the wounds were cleaned and the medication was changed every two days. Compared with other groups, the infected wounds treated with water-soluble oxide wound dressings showed a significant shrinkage trend. On the sixth day, the wounds treated with water-soluble oxide wound dressings had achieved more than 60% wound healing. On the sixth day, the wounds of the blank control group and the vaseline group had not yet begun to heal. In contrast, the appearance of the wounds of the water-soluble oxide wound dressings had begun to heal significantly. The results in Table 3 show that after the wounds of infected mice were treated with water-soluble oxide wound dressings, the wounds could heal about 8 to 12 days earlier.

Antibacterial test

In addition, inhibiting the growth of wound bacteria and protecting the wound from infection are the key points of care. The antibacterial test of Staphylococcus aureus and Aggregatibacter was carried out using the ASTM E2315 method. The steps are as follows.

Step 1: Prepare 20 ml of bacterial culture solution by culturing Staphylococcus aureus for an appropriate period of time and adjust the concentration of the bacterial culture solution to 5x10 ⁵ CFU/mL.

Step 2: Divide the bacterial solution of step 1 into five groups, the five groups are treated for 0 hours, 0.5 hours, 1.0 hours, 2.0 hours and 4.0 hours respectively, each group includes 3 samples, the 3 samples include blank group, experimental group 1 and experimental group 2, the blank group is not added with water-soluble oxide wound dressing; experimental group 1 is added with water-soluble oxide wound dressing including: 55% of the distilled water or mineral water, 15.0% of oxide salt aqueous solution, 3.0% of sea salt Sodium alginate, 2.0% polyvinyl pyrrolidone and 25.0% sodium carboxymethyl cellulose, calculated as a percentage of the total weight of the water-soluble oxide wound dressing; Experimental Group 2: The water-soluble oxide wound dressing was added to include: 55.0% of the mineral water or the distilled water, 20.0% of the oxide salt aqueous solution, 3.0% sodium alginate, 2% polyvinyl pyrrolidone and 20.0% sodium carboxymethyl cellulose, calculated as a percentage of the total weight of the water-soluble oxide wound dressing.

Step 3: Take 0.1 ml of bacterial solution from each sample and evenly apply it on the culture medium. Prepare two replicates of culture medium for each sample, and then culture at 37℃ for 24 hours.

Step 4: Count the number of bacteria and calculate the antibacterial rate using the following formula. Antibacterial rate = original inoculum (Log10) - number of bacteria after sample treatment (Log10) / original inoculum (Log10) x 100%.

As mentioned above, the difference between experimental group 1 and experimental group 2 lies in the oxygen content. The oxygen content of experimental group 2 is higher than that of experimental group 1. As shown in Table 4, high oxygen content increases the antibacterial rate. The antibacterial effect on Staphylococcus aureus can reach an inhibition rate of 99.9%. Secondly, the antibacterial test method of Aggregatibacter is the same as that of Staphylococcus aureus, and its inhibition rate can also reach 99.9%.

Blood oxygen partial pressure

Whether it is venous blood oxygen or arterial blood oxygen in the same individual, the values of pH, _pCO2 , and _pO2 in the blood are similar. After applying water-soluble oxide wound dressings, the _O2 content in the blood will increase and the _CO2 content in the blood will decrease, which can increase the oxygen content in the organism and promote the healing speed of the wound.

The water-soluble oxide wound dressing produced by the manufacturing method of the water-soluble oxide wound dressing of the present invention has the characteristics of sodium carboxymethyl cellulose, polyvinyl pyrrolidone and sodium alginate, which can form a high-viscosity colloid, forming a network polymer colloid containing a large amount of water, with adhesion and good water absorption; the colloid can be repeatedly hydrated when in contact with the body surface, and has the dual functions of providing water to the surface and absorbing exudate, thereby controlling bleeding or loss of body fluids. After absorbing water, the hydrophilic group of sodium carboxymethyl cellulose becomes a gel and adheres to the blood vessel wound surface, and after swelling, a gel layer is formed to stop bleeding of the wound. Secondly, the water-soluble oxide wound dressing forms a protective layer on the wound surface. It is colorless, transparent, and highly water-containing. It maintains the moisture of the wound, avoids friction and irritation of the wound, does not damage the new granulation tissue, and reduces secondary damage. Because sodium carboxymethyl cellulose has an acidic carboxyl group, it combines with Fe ²⁺ in hemoglobin to form a brown viscous gel to seal the end of the capillaries and stop bleeding. In addition, the gel also has an adhesion and aggregation effect on platelets, which can accelerate blood coagulation.

Example 2

Please refer to Figure 3, which is a preparation system for water-soluble oxide wound dressings in Example 2 of the present invention.

As shown in FIG3 , the steps of Example 2 are substantially the same as those of Example 1, except that: in Example 2, before the step of passing the diluted oxide salt solution through the activated carbon adsorption filter 12, an ozone adding step is further included, the diluted oxide salt solution is introduced into an additive tank 16, and the ozone is added into the additive tank 16, and the ozone can sterilize the diluted oxide salt solution.

Human experiments

Please refer to Figures 4A to 4C. Figure 4A is a photograph of the affected part of a diabetic foot taken before the water-soluble oxide wound dressing of the present invention is applied; Figure 4B is a photograph of the affected part of a diabetic foot taken 2 days after the water-soluble oxide wound dressing of the present invention is applied; and Figure 4C is a photograph of the affected part of a diabetic foot taken 7 days after the water-soluble oxide wound dressing of the present invention is applied.

As shown in Figures 4A to 4C, the tester had diabetic foot, and the tendon ligament tissue of the tester had been ruptured, and purulent secretions and necrotic tissue increased. The water-soluble oxide wound dressing of the present invention was applied to the affected part of the patient and the wound healing was observed from 0 to 7 days. The total weight percentage of the water-soluble polymer included: 30.0% sodium alginate, 25.0% polyvinyl pyrrolidone and 25.0% sodium carboxymethyl cellulose, calculated based on 100wt% of the total weight percentage of the water-soluble oxide wound dressing; the ulcer situation improved after 2 days of use, and the wound slowly healed and the wound area was reduced after 7 days of use.

In summary, the water-soluble oxide wound dressing produced by the manufacturing method of the water-soluble oxide wound dressing of the present invention puts the wound in a humid environment, so the tissue protein lytic enzyme in the wound exudate can promote the dissolution and absorption of necrotic tissue; the hypoxic environment stimulates the proliferation of capillaries, which is beneficial to the formation of epithelial cells and collagen. Secondly, the water-soluble oxide wound dressing of the present invention puts the wound in a closed and moisturizing environment, and the dressing forms a barrier to reduce the chance of infection. The slightly acidic environment in a closed state inhibits bacterial growth and is beneficial to the reproduction and function of white blood cells. Furthermore, the water-soluble oxide wound dressing of the present invention helps to release the exudate retained in the wound surface and activate various enzymes and enzyme activation factors. The exudate can also effectively maintain cell survival and promote the release of various growth factors to stimulate cell proliferation. Thus, the water-soluble oxide wound dressing of the present invention has anti-inflammatory reaction and wound smoothing effects, thereby achieving the purpose of accelerating wound healing.

However, the above is only a preferred embodiment of the present invention and is not intended to limit the scope of patent protection of the present invention. Therefore, all equivalent changes made by using the contents of the present invention's specification and drawings are also included in the scope of patent protection of the present invention and are hereby stated.

11: Storage tank

12: Activated carbon adsorption filter

13: Electrolytic magnetization device

14: Flow control valve

15:Magnetic Reactor

151: Water-soluble polymer

Claims (10)

A method for manufacturing a water-soluble oxide wound dressing comprises the following steps: providing a distilled water or a mineral water; adding an oxide salt aqueous solution into the distilled water or the mineral water to form a dilute oxide salt aqueous solution, wherein the oxide salt aqueous solution is formed by passing a high-pressure oxygen into a crystalline salt aqueous solution through a heating electrolysis method, the oxide salt aqueous solution has a pH value of about 5.5 to 8 and a volume molar concentration of 5 to 50 mol/L, and the heating temperature of the heating electrolysis method is The temperature of the dilute oxide salt aqueous solution is controlled between 40 and 80° C.; the dilute oxide salt aqueous solution is passed through an activated carbon adsorption filter to remove trace hydrophobic harmful substances; and the dilute oxide salt aqueous solution is introduced into a magnetizing reactor through a flow control valve to perform a synthesis reaction, and the magnetizing reactor has a magnetic field of 0.1 to 1 Tesla and an electric field of 10 to 100 volts/cm, a synthesis temperature of the magnetizing reactor is controlled between 10° C. and 55° C., and a synthesis pressure is controlled between 6 kg/cm ² to 9 kg/ ^cm2 , a synthesis time of 30 to 90 minutes to form a concentrated active oxide water; the concentrated active oxide water is heated to 65 to 70°C, a water-soluble polymer and the distilled water or the mineral water are added and stirred for 3.5 to 4.5 hours, the stirring speed is controlled at 600 to 650 rpm, and then stirred for 5 to 6 hours under a vacuum state to form a water-soluble oxide wound dressing; wherein the water-soluble oxide wound dressing comprises: 45.0 to 55.0% of the distilled water or the mineral water, 15.0 to 25.0% of an aqueous solution of oxide salts and 30.0 to 35.0% of the water-soluble polymer, based on the total weight percentage of the water-soluble oxide wound dressing. A method for manufacturing a water-soluble oxide wound dressing as described in Item 1 of the patent application, wherein the oxide salt aqueous solution has a volume molar concentration of 10-40 mol/L. The method for manufacturing a water-soluble oxide wound dressing as described in item 1 of the patent application, wherein the water-soluble polymer is sodium alginate, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, hyaluronic acid or any combination thereof. The method for manufacturing a water-soluble oxide wound dressing as described in item 3 of the patent application, wherein the water-soluble polymer comprises: 1.0-30.0% sodium alginate, 1.0-25.0% polyvinyl pyrrolidone and 1.0-25.0% sodium carboxymethyl cellulose, calculated as a percentage of the total weight of the water-soluble oxide wound dressing. The method for manufacturing a water-soluble oxide wound dressing as described in item 1 of the patent application further includes a step of adding an additive, introducing the diluted oxide salt aqueous solution into an additive tank, and adding ozone into the additive tank for sterilization. The method for manufacturing a water-soluble oxide wound dressing as described in item 1 of the patent application, wherein the oxide salt aqueous solution is an aqueous solution composed of a metal element cation and a carbonate, sulfate, chromate, tungstate, molybdate, phosphate, arsenate or vanadate. A method for manufacturing a water-soluble oxide wound dressing as described in item 6 of the patent application, wherein the metal element cation includes at least one divalent or trivalent metal cation, which is Fe ²⁺ , Cu ²⁺ , Zn ²⁺ , Pb ²⁺ , Mn ²⁺ , Bi ³⁺ or any combination thereof. A method for manufacturing a water-soluble oxide wound dressing as described in Item 1 of the patent application, wherein the thickness of the water-soluble oxide wound dressing is greater than 0.1 mm and less than 4 mm. As described in item 1 of the patent application scope, the method for manufacturing a water-soluble oxide wound dressing, wherein the flow control valve controls the flow rate of the diluted oxide salt aqueous solution to 500~8000L/min. A water-soluble oxide wound dressing produced by the manufacturing method described in any one of items 1 to 9 of the patent application scope.